Elanco Launches New Canine Dermatitis Treatment Befrena
Elanco announced the phased launch of Befrena - tirnovetmab -, a new anti-IL-31 monoclonal antibody injection for treatment of canine allergic and atopic dermatitis. Befrena expands Elanco's dermatology portfolio by offering a new treatment option that starts controlling allergic itch within 24 hours. Befrena is claimed to offer at least 6 to 8 weeks of itch relief, in contrast to the 4 to 8 weeks of the current market incumbent, lokivetmab, and to start controlling itch within 24 hours. Elanco received approval of Befrena from the USDA in December 2025.
